AIRO2023

BOLOGNA, 27-29 OTTOBRE 2023

PALAZZO DEI CONGRESSI

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti





BOLOGNA, 27-29 OTTOBRE 2023 PALAZZO DEI CONGRESSI

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

Multiple oligometastases treated with single course stereotactic ablative radiotherapy (SABR): outcome and predictive factors

Vernier V^{1,2}, Franzese C^{1,2}, Franceschini D², ComitoT², Navarria P², Clerici E², Teriaca MA², Massaro M², Di Cristina L^{1,2}, Marini B^{1,2}, Galdieri C², Mancosu P², Tomatis S², Scorsetti M^{1,2}

¹ Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano Milan, Italy ² Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele - Milan, Italy



AIRO2023

BACKGROUND

- Oligometastatic disease (OMD), defined as 1-5 metastatic lesions, can be safely treated with SRT
- Delivering SRT in patients with multiple metastases remains a challenge from both clinical and technical perspectives
- Only a few patients with 3 or more lesions have been included in most studies on the oligometastatic disease

PURPOSE

- → To evaluate survival and toxicity of a large sample of patients affected by multiple oligometastases treated with single course SABR
- \rightarrow To investigate the association of clinical features on patients' outcome



AIRO2023

METHODS

- Retrospective cohort of OM patients with 3 to 5 extracranial metastases from any solid tumour treated with a single course of SBRT from 2012 to 2020.
- All patients were treated with volumetric modulated arc therapy (VMAT) technique with ablative intent.
- Endpoints of the analysis were overall survival (OS), progression free survival (PFS), local control (LC) and pattern of toxicity.
- Univariate analisys and multivariate Cox regression (backward conditional) model were carried out to evaluate the association between clinical factors and survival.



AIRO2023

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

BASELINE CHARACTERISTICS

N=136

Age (years) Mean Range	67.8 28.0-87.1
Sex Male Female	80 (58,8) 56 (41,2)
Performance status 0 1 2	91 (66,9) 36 (26,5) 9 (6,6)
Primary tumor site Colorectal Lung Breast Prostate Other	60 (44,1) 16 (11,8) 7 (5,1) 8 (5,9) 45 (33,1)
Primary tumor histology Adenocarcinoma Other	110 (80,8) 26 (19,2)
Metastatic presentation Synchronous Metachronous	39 (28,7) 97 (71,3)
Disease-free interval (months) Range	14,1 0-222,1

Oligometastatic presentation De novo sincrono De novo metacrono oligorecurrence De novo metacrono oligoprogression Repeat oligorecurrence Induced oligorecurrence Induced oligopersistence Induced oligoprogression	6 (4,4) 20 (14,7) 2 (1,5) 25 (18,4) 59 (43,4) 16 (11,8) 8 (5,9)
Prior local ablative treatment No Yes	82 (60,3) 54 (39,7)
Prior systemic therapy No 1 line 2 lines ≥3 lines	36 (26,5) 43 (31,6) 35 (25,7) 22 (16,2)
Number of metastases treated 3 4 5	102 (75,0) 26 (19,1) 8 (5,9)
Total tumour volume (cc) Median Range	19,1 0,6 – 245,1

Irradiated lesions sites	47 (04 0)
Lung	47 (34,6)
Liver	31 (22,8)
Lymph nodes	19 (14,0)
Lung + lymph node	11 (8,1)
Lung + liver	10 (7,3)
Others	11 (8,1)
Number of treated organs	
1	97 (71,3)
2	36 (26,5)
3	3 (2,2)
Presence of extra-target disease	
No	119 (87,5)
Yes	17 (12,5)
Concomitant systemic therapy	
No	102 (75,0)
Yes	34 (25,0)
Dose (EQD2, Gy)	
Median	83.3
	37,5 - 218,7
	64 (47,1)
	15 (11,0)
Range <50 Gy 50-70 Gy 70-100 Gy >100Gy	18 (13,2) 39 (28,7) 64 (47,1)




BOLOGNA, 27-29 OTTOBRE 2023 PALAZZO DEI CONGRESSI

AIRO2023

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

RESULTS

Median follow-up was 25.0 months



- Rates of LC at 1 and 3 years were 89.3% and 76.5%.
- In terms of toxicity, no grade 3 or higher toxicity was reported both in the acute and late settings.



AIRO2023

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

UNIVARIATE ANALYSIS

Four factors were associated with worse OS:


1.	Higher age	p=0.003
2.	Higher ECOG performance status (PS)	p<0.001
3.	Lower EQD2	p=0.024
4.	Higher total tumour volume (TTV)	p<0.001



AIRO2023

MULTIVARIATE ANALYSIS

Only higher TTV was an independent predictive factor of worse OS and PFS.





AIRO2023

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

CONCLUSIONS

- Patients affected by 3 to 5 oligometastases can be safely treated with a single course of SABR with encouraging survival outcomes
- Total tumor volume seems to be a better predictor of survival than the number of lesions treated

Prospective trials are expected to confirm these results on larger population including patients with 1 -2 or more than 6 metastases or in case of intracranial disease



AIRO2023

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti



